COMMUNIQUÉS West-GlobeNewswire

Seres Therapeutics to Participate in Piper Sandler Healthcare Conference
24/11/2025
CAMBRIDGE, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will participate in a fireside chat at the Piper [...]
Ocular Therapeutix™ Announces First Patient Randomized in HELIOS-3 Phase 3 Registrational Program for AXPAXLI™ in NPDR
24/11/2025
First patient randomized into HELIOS-3, which along with HELIOS-2 form the basis of AXPAXLI’s registrational program in non-proliferative diabetic retinopathy (NPDR) HELIOS-2 and HELIOS-3 are global, complementary [...]
Vaxil Announces Update on Non-Brokered Private Placement
24/11/2025
Not for distribution by US newswire or in United States NESS-ZIONA, Israel, Nov. 24, 2025 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (" Vaxil " or the " Company ") (TSX VENTURE: VXL) is pleased to announce that the Company, [...]
Kymera Therapeutics to Participate in Upcoming December Investor Conferences
24/11/2025
WATERTOWN, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological [...]
Biomea Fusion to Participate at Upcoming Investor Conferences
24/11/2025
SAN CARLOS, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it will [...]
Sionna Therapeutics to Participate in Upcoming December Investor Conferences
24/11/2025
WALTHAM, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF [...]
Tonix Pharmaceuticals Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder
24/11/2025
Tonix plans to initiate potential pivotal Phase 2 HORIZON study of TNX-102 SL in adults with major depressive disorder in mid-2026 More than 21 million US adults experience a major depressive episode each year CHATHAM, [...]
CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference
24/11/2025
Late-breaking oral presentation by a leading global authority in Dementia with Lewy bodies (DLB) to highlight updated data from Phase 2b study on neflamapimod treatment for DLB New data demonstrating the utility of [...]
Fortrea Completes $75.7 Million Senior Notes Tender Offer Utilizing Cash on Hand
24/11/2025
DURHAM, N.C., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it has completed its debt tender offer (the “Tender [...]
Tilray dévoile les produits de vapotage Good Supply au Québec avec l’introduction récente des produits de vapotage au Québec
24/11/2025
TORONTO, 24 nov. 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (« Tilray ») (Nasdaq : TLRY ; TSX : TLRY), un leader mondial des biens de consommation, de l’industrie du cannabis, des boissons et du bien-être, annonce [...]
Tilray Unveils Good Supply Vapes in Québec Following the Recent Introduction of Vape Products in Québec
24/11/2025
TORONTO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc., company (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of the cannabis, beverage, and [...]
Cardiff Oncology to Present at the Piper Sandler 37th Annual Healthcare Conference
24/11/2025
SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced [...]
Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)
24/11/2025
NEW HAVEN, Conn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that multiple [...]
Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness
24/11/2025
VBY329 is designed for the prevention of Respiratory Syncytial Virus (RSV) infections in newborns, infants, and children, and results from Invivyd’s proprietary antibody discovery technology platform VBY329 meets [...]
Clearside Biomedical to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process
24/11/2025
- Intended to Maximize Stakeholder Value Through Structured Process - - Validated SCS Microinjector ® Delivery Platform Anchored by Commercial Product and Five Suprachoroidal Licensing Collaborations with Future Royalty [...]
Vera Therapeutics to Participate at Upcoming Investor Conferences
24/11/2025
BRISBANE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients [...]
Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ™ in Leptomeningeal Metastases
24/11/2025
HOUSTON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous [...]
Landmark CREST-2 Study Published in the New England Journal of Medicine Highlights the Benefits of Carotid Artery Stenting
24/11/2025
Carotid artery stenting combined with medical therapy demonstrated a significantly lower stroke risk compared to intensive medical therapy alone in patients with severe asymptomatic carotid stenosis MIAMI, Nov. 24, 2025 [...]
Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions
24/11/2025
Oral macrocyclic peptides have the potential to offer biologic-like efficacy and safety in a convenient oral format Collaboration further advances Biogen’s immunology strategy by broadening its early-stage pipeline and [...]

Pages